Oncodesign Precision Medicine - OPM
Philippe Genne is a seasoned leader in cancer treatment research and development, currently serving as the PDG of Oncodesign Precision Medicine (OPM), a company established in Dijon in September 2022. Previously, Philippe Genne founded Oncodesign in 1995, also focused on discovering new anticancer therapies. Earlier career experience includes serving as the International Project Manager at Debiopharm, where responsibilities involved clinical development, and conducting research at Texinfine and GSK. Philippe Genne holds advanced degrees in pharmacology and immunology from Université de Bourgogne and Université Claude Bernard Lyon 1.
This person is not in any teams
Oncodesign Precision Medicine - OPM
OPM is a technological company specialized in precision medicine. OPM's mission is to bring innovative therapeutic and diagnostic solutions to treat therapeutic resistance and metastasis evolution. The patient is at the centre of our reflexion, of our unique innovative model, and our investments. For OPM "our collective success is paramount", there can be no value creation without exchange, without dialogue. The value creation resulting for us from reciprocity, i.e. balanced and fair exchanges at all levels, whether between internal collaborators, or with our partners, therapists, patients, experts and investors. To discuss partnership or investment, don't hesitate to get in touch : info@oncodesign.com